Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter

Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter

Simon A Braithwaite,1 Bruce D Braithwaite2 1University College Hospital Medical School, London, UK; 2Department of Cardiovascular Medicine, University of Nottingham, Nottingham, UK Abstract: The Closure Fast™ Endovenous Radiofrequency Ablation Catheter is the latest version of a minimall...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Braithwaite SA, Braithwaite BD
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2014
Materias:
Medical technology
R855-855.5
Acceso en línea:https://doaj.org/article/fc14e5c13dda492287d1095219956eaa
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:fc14e5c13dda492287d1095219956eaa
record_format dspace
spelling oai:doaj.org-article:fc14e5c13dda492287d1095219956eaa2021-12-02T02:09:10ZClinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter1179-1470https://doaj.org/article/fc14e5c13dda492287d1095219956eaa2014-06-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-of-the-covidien-closure-fasttrade-endovenous-radiofre-a17104https://doaj.org/toc/1179-1470 Simon A Braithwaite,1 Bruce D Braithwaite2 1University College Hospital Medical School, London, UK; 2Department of Cardiovascular Medicine, University of Nottingham, Nottingham, UK Abstract: The Closure Fast™ Endovenous Radiofrequency Ablation Catheter is the latest version of a minimally invasive system for the treatment of patients with superficial venous disease. The Closure Fast™ catheter heats the vein wall to 120°C, causing denaturation of the collagen of the vein wall and contraction of the vessel such that no blood can flow through it. Nearly one million systems have been sold since the product was launched. Many, if not all, patients can be treated under local anesthesia with the Closure Fast™ catheter. Duplex ultrasound reports occlusion rates for the treated vein of 94%–98% at 1 year and 85%–93% at 3 years. The system produces average postoperative pain scores of less than 2 out of 10 on a visual analog score. In the first postoperative week, 76% of patients do not require analgesia. Some 45% of patients return to normal activity on the first postoperative day. Serious complications appear to be rare following the Closure Fast™ procedure. Transient paresthesia occurs in 0.2% of cases, thrombophlebitis in 1%–10%, and thromboembolic events in up to 1.4%, mainly heat-induced thrombosis. Closure Fast™ adds significant costs to treating superficial venous disease but studies have shown it to be cost-effective when used in an office setting. Keywords: Closure Fast, catheter, Endovenous Radiofrequency Ablation CatheterBraithwaite SABraithwaite BDDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2014, Iss default, Pp 179-185 (2014)
institution DOAJ
collection DOAJ
language EN
topic Medical technology
R855-855.5
spellingShingle Medical technology
R855-855.5
Braithwaite SA
Braithwaite BD
Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter
description Simon A Braithwaite,1 Bruce D Braithwaite2 1University College Hospital Medical School, London, UK; 2Department of Cardiovascular Medicine, University of Nottingham, Nottingham, UK Abstract: The Closure Fast™ Endovenous Radiofrequency Ablation Catheter is the latest version of a minimally invasive system for the treatment of patients with superficial venous disease. The Closure Fast™ catheter heats the vein wall to 120°C, causing denaturation of the collagen of the vein wall and contraction of the vessel such that no blood can flow through it. Nearly one million systems have been sold since the product was launched. Many, if not all, patients can be treated under local anesthesia with the Closure Fast™ catheter. Duplex ultrasound reports occlusion rates for the treated vein of 94%–98% at 1 year and 85%–93% at 3 years. The system produces average postoperative pain scores of less than 2 out of 10 on a visual analog score. In the first postoperative week, 76% of patients do not require analgesia. Some 45% of patients return to normal activity on the first postoperative day. Serious complications appear to be rare following the Closure Fast™ procedure. Transient paresthesia occurs in 0.2% of cases, thrombophlebitis in 1%–10%, and thromboembolic events in up to 1.4%, mainly heat-induced thrombosis. Closure Fast™ adds significant costs to treating superficial venous disease but studies have shown it to be cost-effective when used in an office setting. Keywords: Closure Fast, catheter, Endovenous Radiofrequency Ablation Catheter
format article
author Braithwaite SA
Braithwaite BD
author_facet Braithwaite SA
Braithwaite BD
author_sort Braithwaite SA
title Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter
title_short Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter
title_full Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter
title_fullStr Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter
title_full_unstemmed Clinical utility of the Covidien Closure Fast™ Endovenous Radiofrequency Ablation Catheter
title_sort clinical utility of the covidien closure fast™ endovenous radiofrequency ablation catheter
publisher Dove Medical Press
publishDate 2014
url https://doaj.org/article/fc14e5c13dda492287d1095219956eaa
work_keys_str_mv AT braithwaitesa clinicalutilityofthecovidienclosurefasttradeendovenousradiofrequencyablationcatheter
AT braithwaitebd clinicalutilityofthecovidienclosurefasttradeendovenousradiofrequencyablationcatheter
_version_ 1718402690865692672

Ejemplares similares